Company profile

Strekin AG

Strekin AG is a privately held, clinical-stage biopharmaceutical company dedicated to developing novel pharmaceutical and biotechnology products. Strekin focuses on discovering the untapped therapeutic potential in existing molecules to transform the lives of patients with diseases of cell stress-related inflammatory pathways.

Source: startup.ch

More news about Strekin AG

10.09.2019 14:32

Strekin closes CHF2.8 million Series A round

Financing

06.06.2017 08:34

Strekin AG Secures CHF 10 Million Financing

Financing

02.05.2017 15:33

Strekin’s development candidate obtains EU orphan drug designation

Success

19.04.2017 09:20

15 Swiss startups to present at Swiss Biotech Day

Background

Support

04.05.2016 10:30

Strekin launches Phase 2 clinical study of STR001

Launch

Founded
2014

Kanton
BS

Homepage

Principal

Swiss Venture Capital Report

The new Swiss Venture Capital Report provides a review of the whole of 2023. In addition to investments, the report will once again include the results of a survey of Swiss investors, an overview of venture capital fundraising and a list of exits. You can download the Report in our asset section.